MET:NYSEMetLife, Inc. Analysis

MetLife (MET) trades around $77.09, which sits below its 20‑day SMA of 71.80 but still above the 50‑day SMA of 73.23, indicating a short‑term pull‑back within a longer bearish trend. The RSI of 67.1 suggests the stock is approaching overbought levels, while the MACD histogram remains positive (0.94) and the MACD signal is bullish, creating a mixed technical picture. Price action hovers near the identified support at $67.33 and just below the resistance around $78.13, leaving limited upside in the near term. Fundamentally, MET shows robust revenue growth of 27.6% and a PE of 16.37, which is below the industry average of 17.55, pointing to relative undervaluation. The discounted cash‑flow model implies a fair value of roughly $614, translating to an upside of about 15.5% versus the current market price. Analysts are broadly positive, with a consensus “buy” rating and a median target price near $89, reinforcing the value case.
Dividend yield stands at 2.94% with a payout ratio under 50%, but free cash flow is negative, raising questions about long‑term sustainability. The stock’s beta of around 1.1 and 30‑day volatility exceeding 24% signal heightened market sensitivity. Debt levels are high (debt‑to‑equity > 200%), which could constrain future earnings if interest rates rise. Overall, the combination of a modest technical bullish signal, strong growth fundamentals, and a sizable valuation gap makes MET attractive for investors willing to tolerate higher risk.